Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma
Open Access
- 8 March 2021
- Vol. 13 (5), 1152
- https://doi.org/10.3390/cancers13051152
Abstract
Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum–etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC.This publication has 97 references indexed in Scilit:
- Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer PatientsJournal of Thoracic Oncology, 2012
- A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancerLung Cancer, 2011
- PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activityBritish Journal of Pharmacology, 2010
- Small Cell Lung Cancer: Are We Making Progress?The American Journal of the Medical Sciences, 2010
- Platinum versus non-platinum chemotherapy regimens for small cell lung cancerPublished by Wiley ,2008
- Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702British Journal of Cancer, 2007
- Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysisLung Cancer, 2000
- A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinomaCancer, 1998